SIM1803-1A
/ Simcere, WuXi AppTec
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
January 13, 2021
An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.
(clinicaltrials.gov)
- P1; N=243; Recruiting; Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Oncology • Solid Tumor
December 17, 2020
An Open, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.
(clinicaltrials.gov)
- P1; N=243; Not yet recruiting; Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Clinical • New P1 trial • Oncology • Solid Tumor
November 18, 2020
Simcere kicks off China Phase I for innovative multi-kinase inhibitor
(GBI Health)
- "GBI SOURCE database indicates that China-based Simcere Pharmaceutical Group (2096.HK) has initiated a Phase I clinical study (CTR20202292) for SIM1803-1A, a next-generation kinase inhibitor targeting TRK A/B/C and ROS1. The drug is set to be developed as a treatment for locally advanced/metastatic solid tumors with mutations of NTRK, ROS1, and ALK fusion genes."
New P1 trial • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1